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ABSTRACT
Recent advances in basic and clinical researches of nonsteroidal anti-inflammatory drugs (NSAIDs) are re-
viewed. Concerning arachidonic acid cascade, recent studies revealed that not only cyclooxygenase (COX) but
also terminal enzymes such as prostaglandin E synthase are very important in the understanding of the patho-
genesis of inflammation and mechanisms of action of NSAIDs. We also found that some conventional NSAIDs
and a selective COX-2 inhibitor exert pro-apoptotic effect on synovial fibroblasts and several cancer cells by
COX-independent mechanisms. Clinical indications for use of NSAIDs are broad and include the following :
rheumatic diseases ; painful andor febrile conditions ; and prevention from thrombotic diseases such as myo-
cardial infarction. In addition, recently developed selective COX-2 inhibitors have been found to be nearly as ef-
fective for the same conditions as conventional NSAIDs except with regard to the prevention of thrombosis.
The incidence of severe gastrointestinal events in patients treated with selective COX-2 inhibitors has been
proven to be lower than patients treated with conventional NSAIDs. However, there was no difference in renal
complications between the two groups. Instead, an increased incidence of myocardial infarction after admini-
stration of selective COX-2 inhibitors may occur in patients with risk factors for atherosclerotic or thrombotic
complications. Further basic and clinical studies remain to be investigated in the future．
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INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are
drugs with activity against inflammatory symptoms
but without any glucocorticoid action. In 1971, Vane1
discovered that inhibition of cyclooxygenase (COX)
was the major mechanism of action for aspirin and
some other NSAIDs. COX-2, an isozyme of COX, was
subsequently discovered,2-4 and selective COX-2 in-
hibitors with an expected lower incidence of adverse
reactions have been approved and released in recent
years. This paper introduces recent advances in basic
and clinical research on NSAIDs．
MECHANISMS OF ACTION OF NSAIDS
INHIBITION OF COX
As the features of COX-1 and COX-2 have already
been explained in many reviews, a simple overview
including our recent findings is discussed as follows.
Arachidonic acid is released from the cell membrane
phospholipids by phospholipase (PL) A2. COX is a
rate-limiting enzyme that metabolizes arachidonic
acid to various physiologically active substances such
as prostaglandins (PGs). One of the major routes of
metabolism for arachidonic acid is transformation
from arachidonic acid into PGG2 by the enzymatic ac-
tivity of COX, and further metabolism to PGH2 by the
peroxygenase activity of this enzyme. COX-2 is also
suggested to have the same enzymatic activities as
those of COX-1. NSAIDs demonstrate anti-
inflammatory action by inhibiting COX, thereby in-
hibiting the production of inflammatory chemical me-
diators such as PGE2 and PGI2.
A part of the arachidonic acid cascade and meta-
bolic pathways in the syntheses of PGs and
thromboxane (TX) are shown in Figure 1. In recent
years, cDNAs for the enzymes involved in the meta-
bolic process after PGH2 have been cloned and the
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Fig. 1 A scheme of metabolic pathways from arachidonic acid to various kinds of 
prostaglandins (PGs) and thromboxane (TX). PGES: PGE synthase.
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Fig. 2 Co-location of membrane-associated prostaglandin E synthase (mPGES) and cyclooxy-
genase (COX)-2 in interleukin-1β-stimulated rheumatoid synovial fibroblasts.
mPGES COX-2
structures of the proteins have been identified . 5
These enzymes are labeled in the following manner :
PGE synthase(PGES) for PGE2; PGDS for PGD2;
PGFS for PGF2α; PGIS for PGI2(prostacyclin) ; and
TXS for TX productions. Isozymes of PLA2, COX, and
the various PG or TX synthases are involved in the
metabolism of arachidonic acid, and it has been found
that they are closely linked with each others . 5 Re-
cently, we showed that the expression of microsomal
or membrane-associated PGES (mPGES , also re-
cently called as mPGES-1) in the synovial fibroblasts
from patients with rheumatoid arthritis (RA) were in-
duced by stimulation of interleukin (IL) -1β.6 COX-2
expression is also induced simultaneously, and these
enzymes are co-located intracellularly (Fig. 2) and co-
operate to maintain PGE2 production . It was also
found that IL-1β -induced mPGES expression in RA
synovial fibroblasts is enhanced by PGE2 itself, show-
ing an autoregulatory action.7 A scheme of this action
is shown in Figure 3. In the near future , mPGES
could be a novel target for a novel anti-inflammatory
agent with a higher specific action for suppression of
PGE2 production than COX-2 inhibitors．
In 1991, COX-2 was discovered as an isozyme of
COX that is expressed after stimulation with mito-
gens , while COX-1 is constitutively expressed by
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Fig. 3 A scheme of autoregulation of prostaglandin (PG) 
E2 production via enhanced expression of membrane-asso-
ciated prostaglandin E synthase (mPGES) by PGE2 itself in 
proinflammatory cytokine-induced rheumatoid synovial cels.
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Fig. 4 Celecoxib-induced apoptosis in rheumatoid syno-
vial fibroblasts. Apoptotic cels were detected by TUNEL 
assay.
many different kinds of cells. For example, TXA2 is
produced in platelets by only COX-1, and has a pro-
tective effect by promoting platelet adhesion when
bleeding occurs . PGI2 and PGE2 are produced by
COX-1 in the gastric mucosa, where they protect the
gastro-intestinal mucosa by maintaining blood flow
and increasing mucus secretion. In other words, the
PGs that are produced by COX-1 act as host de-
fenses. On the other hand, COX-2 expression is in-
duced at sites of inflammation and the PGs that are
produced act in the promotion of inflammation as al-
ready described above. Thus, selective COX-2 inhibi-
tors are theoretically suggested to be NSAIDs with
fewer adverse reactions．
ACTIONS OTHER THAN COX INHIBITION
The major mechanism of action of NSAIDs has been
explained as COX inhibition, however there are also
phenomena that cannot be explained by this effect
alone. Recently, it was found that treatment with high
concentrations of several conventional NSAIDs (such
as indometacin and diclofenac) induce apoptosis in
the synovial fibroblasts of RA patients . 8 Moreover ,
there was a positive correlation between PPARγ acti-
vation and pro-apoptotic action induced by these
NSAIDs. We also reported that induction of apoptosis
was only found in relatively lower concentrations of
celecoxib incubated with the RA synovial fibroblasts
(Fig. 4), whereas various other selective COX-2 in-
hibitors including etodolac, meloxicam, nimesulide,
NS398, and rofecoxib, even with higher concentra-
tions were not identified.9 In this case, however, cele-
coxib did not stimulate PPARγ activation in these
cells . Although the mechanism of the celecoxib-
induced apoptosis is still unclear, in addition to acting
as anti-inflammatory drug, celecoxib or some conven-
tional NSAIDs may also act as a disease modifying
anti-rheumatic drug．
COX-2 SELECTIVITY
After the establishment of the COX-2 theory, develop-
ment of novel COX-2 inhibitors was rapid . Even
among conventional NSAIDs, however , there exist
some with considerable COX-2 selectivity , such as
etodolac and meloxicam . These COX-2 inhibitors
which have been marketed in Japan and other coun-
tries show a low rate of serious gastrointestinal com-
plications.10 On the other hand, celecoxib and rofe-
coxib are drugs designed with specific binding to
COX-2 molecules and have already been marketed in
many major foreign countries except Japan．
The method of measuring COX-2 selectivity varies
widely among reports. In general, if clinical useful-
ness is to be considered, a method that uses human
cells is most appropriate . 11 Etodolac , meloxicam ,
celecoxib , rofecoxib , valdecoxib and etoricoxib all
show selectivity for COX-2 based on multiple reports
using human cells. These drugs are clinically avail-
able as COX-2 inhibitors approved in other countries,
whereas only etodolac and meloxicam have been ap-
proved in Japan. There is also an argument that so-
called coxibs must be differentiated from non-coxib
COX-2 inhibitors that were developed earlier. Regard-
ing such controversy, Vane et al. 12 have suggested
that the degree of selective inhibition of COX-2
should be the most important factor. If COX-2 selec-
tivity is observed, drugs must be labeled as selective
COX-2 inhibitors or COX-1 sparing NSAIDs. Indeed,
it should be stressed that coxib is the term for a
chemical structure, just like oxicam, for example. In
addition, adjective terms for COX-2 inhibitors, such
as preferential , selective, and specific , do not have
any significant meaning．
Allergology International Vol 54, No2, 2005 www.js-allergol.gr.jp 211
Advances in NSAIDs
Table 1　A comparison between large-scale clinical trials of celecoxib and rofecoxib
VIGOR (Bonbardier)CLASS (Silverstein)Clinical Trials
NEJM 343: 1520, 2000JAMA 284: 1247, 2000
RA (n=8,076)OA・RA (n=8,059)Subjects
Rofecoxib (50 mg/day)Celecoxib (800 mg/day)Drugs
Naproxane (1000 mg/day)Ibuprofen (2400 mg/day)Control Drugs
Diclofenac (150 mg/day)
Severe GI Complications
60% (p=0.005)50% (p=0.09)Reduction Rate
equal・Aspirin User (20%)
60%・non-Aspirin (80%)
Increased (0.4% vs 0.1%)equalMyocardial Infarction
CLINICAL APPLICATIONS OF SELECTIVE
COX-2 INHIBITORS
NSAIDs have a long history of use dating back to the
era of herbal medicines, and their indications are ex-
tremely broad , including such conditions as rheu-
matic and musculoskeletal diseases, painful illnesses,
fever , and prevention from thrombotic and athero-
sclerotic events (myocardial and cerebral infarctions,
etc). In addition, indications for several kinds of tu-
mors , Alzheimer’s disease , and other conditions
have recently been discussed. The clinical application
of NSAIDs or COX-2 inhibitors for these indications
are outlined below．
RHEUMATIC DISEASES AND MUSCULOSKELE-
TAL DISEASES
The following is a discussion of the results of a clini-
cal study on celecoxib that was conducted on RA pa-
tients13 in the U.S.A. The percentages of patients with
RA who achieved equal and more than 20% improve-
ments are estimated using criteria established by
American College of Rheumatology (ACR).14 Com-
pared with placebo , celecoxib was superior at all
doses (200―800 mgday), and the results were also
either equal or superior as compared with naproxen
(1,000 mgday ). Rofecoxib had an effect on RA that
was almost the same as conventional NSAIDs. 15 In
other words , when , compared to anti-rheumatic
drugs such as methotrexate, NSAIDs even selective
COX-2 inhibitors were clearly inferior.16 In addition,
most reports on the clinical efficacy of selective COX-
2 inhibitors for osteoarthritis were nearly equivalent
to conventional NSAIDs．
OTHER PAINFUL CONDITIONS AND FEVER
Pain is one of the most important joint symptoms in
RA, but the extent to which COX-2 is involved in the
manifestation of pain is unknown. In general, COX-2
has been shown to be involved in the perception of
central pain , while COX-1 is involved in peripheral
pain . However , a report 17 that compared selective
COX-2 inhibitors (rofecoxib 50 mg and celecoxib 200
mg ) with a conventional drug (ibuprofen 400 mg) for
dental pain revealed that selective COX-2 inhibition
achieved an analgesic effect equal or better than con-
ventional drugs which inhibit both COX-1 and COX-2.
The plasma half-life of ibuprofen is shorter than that
of rofecoxib or celecoxib, and as can be clearly ex-
pected, the efficacy of each drug was consistent with
changes in the plasma concentration . The mecha-
nism for induction of systemic fever involves stimula-
tion of the hypothalamic regions in the brain by PGE2
via COX-2, and the antipyretic effect of selective COX-
2 inhibitors was also suggested to be the same as that
of conventional drugs．
ANTITHROMBOTIC AND ANTIPLATELET EF-
FECTS
This effect is obtained by a reduction of TXA2 produc-
tion through inhibition of COX-1, so selective COX-2
inhibitors cannot be used for this purpose. In fact ,
this action is recognized as an indication for low-dose
aspirin only,18 and even other conventional NSAIDs
that inhibit COX-1 are not satisfactory for this pur-
pose.19 In contrast to other conventional NSAIDs, as-
pirin inhibits COX-1 irreversibly by acetylation, and a
potent and prolonged effect is obtained even at low
doses. With selective COX-2 inhibitors, there is the
converse possibility of complications related to
thrombosis as mentioned below．
PATENT DUCTUS ARTERIOSUS IN PREMATURE
INFANTS
When NSAIDs are used during pregnancy, there is
the risk of ductus arteriosus occlusion in the fetus,
but this action can also be used to treat patent ductus
arteriosus in premature infants. This indication has
only been approved for the non-selective COX inhibi-
tor, injectable indometacin, but recent experiments
have shown that PGI2 produced by COX-2 is linked to
ductus arteriosus patency. There is thus the possibil-
ity that further investigations will lead to the use of
selective COX-2 inhibitors for this condition．
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OTHER DISEASES SUCH AS TUMORS
There are several epidemiologic studies that indicate
a lower incidence of various malignant diseases in
NSAID users. There are also many basic studies that
have shown NSAIDs can inhibit the proliferation of
various cancer cell lines in vitro, therefore implicat-
ing an anti-tumor effect by NSAIDs. In general, high
concentrations of NSAIDs are required to produce
this anti-tumor effect , and thus selective COX-2 in-
hibitors that are known to have few adverse drug re-
actions are attracting attention because higher doses
could be administered.20 In a clinical study,21 patients
with familial adenomatous polyposis received either
of 2 doses of celecoxib or placebo for 6 months, and
the number of colorectal polyps was significantly re-
duced in the group that took 400 mg of celecoxib
twice daily. Recently, Sonoshita et al.22 showed that
PGE2 promotes polyp formation in the intestines of
mice via the EP2 receptor, suggesting that at least
part of the anti-tumor effect of COX-2 inhibitors is me-
diated via inhibition of PGE2. However, as previously
mentioned, the induction of apoptosis9 in RA synovial
fibroblasts is specific to celecoxib. Furthermore, only
celecoxib among 6 selective COX-2 inhibitors has
been found to induce apoptosis of colon cancer cell
lines.23 Therefore, we suggest that this reduction of
number of polyps is not only due to COX-2 inhibition
but that there is a possibility of direct pro-apoptotic
action also being involved．
Epidemiological studies indicate that NSAIDs de-
crease the risk of developing Alzheimer’s disease
(AD).24 Their beneficial effects may be due to inter-
ference in the chronic inflammatory reaction that
takes place in AD. So far, however, clinical trials de-
signed to inhibit inflammation or COX-2 activity by
conventional NSAIDs or selective COX-2 inhibitors
have failed in the treatment of AD patients．
ADVERSE DRUGS REACTIONS OF SELEC-
TIVE COX-2 INHIBITORS
GASTROINTESTINAL COMPLICATIONS
Several clinical studies have shown that the incidence
of severe gastrointestinal complications is lower for
etodolac and meloxicam when compared with con-
ventional NSAIDs.10 However, since the development
of celecoxib and rofecoxib were initially designed as
COX-2 specific inhibitors, there has been progress in
clinical research , and more rigorously conducted
studies are being published．
First, a clinical study on celecoxib in which short-
term gastrointestinal safety data were determined by
endoscopy showed that the incidence of gastroduode-
nal ulcers after 12 weeks of treatment (even at the
maximum dose of 800 mgday ) was not different
from that in the placebo group.13 Next, the CLASS
and VIGOR studies on celecoxib25 and rofecoxib26,
respectively , were reported almost simultaneously.
These were both large-scale randomized controlled
studies that enrolled 8,000 or more patients (Table 1).
In the CLASS study, serious gastrointestinal compli-
cations were decreased by approximately 50% in the
celecoxib group compared with the reference ibupro-
fen or diclofenac groups, although there was no sig-
nificant difference. In the VIGOR study, however, se-
rious gastrointestinal complications were significantly
decreased by approximately 60% in the rofecoxib
group compared with the naproxen group . In the
CLASS study, 20% of the patients were treated con-
comitantly with low-dose aspirin for the prevention of
myocardial infarction. When only the patients on con-
comitant aspirin therapy were compared, there was
no difference between the two groups. However, the
decrease in the rate of serious gastrointestinal com-
plications among patients without concomitant treat-
ment with aspirin was the same as in the VIGOR
study．
COX-2 has been detected in experimental gastric
ulcer tissue of rats. Since COX-2 is involved in ulcer
healing, administration of selective COX-2 inhibitors
to rats after ulceration was reported to cause pro-
longed ulcer healing . 27 It was also suggested by
analysis of the CLASS data that selective COX-2 in-
hibitors do not necessarily reduce gastrointestinal
complications compared with conventional drugs.28
However, if the various clinical studies conducted to
date are compiled, it seems that selective COX-2 in-
hibitors caused a lower rate of gastrointestinal com-
plications as a whole when compared with conven-
tional NSAIDs．
RENAL IMPAIRMENT
In a clinical study on RA patients, the same percent-
ages of edema were observed in the celecoxib and
naproxen groups.13 There were no cases of edema in
the placebo group , which suggested that selective
COX-2 inhibitor also caused renal blood flow impair-
ment and accumulation of sodium as found in other
conventional drugs . COX-2 is constitutionally ex-
pressed by some renal cells,29 and this could be a fac-
tor in renal impairment. In addition to such mild im-
pairment, serious renal impairment due to selective
COX-2 inhibitors has also been reported.30 This is an-
other topic for further investigation.
MYOCARDIAL INFARCTION AND OTHER
THROMBOTIC DISEASES
Although the VIGOR and CLASS studies revealed a
decrease in serious gastrointestinal damage side ef-
fects , there was also evidence warning of new ad-
verse drug reactions associated with selective COX-2
inhibitors. The incidence of myocardial infarction was
significantly increased by approximately 4-fold in the
rofecoxib group compared with the naproxen group
in the VIGOR study (Table 1). Further analysis of the
CLASS study31 has also revealed that ischemic heart
disease was increased with the use of celecoxib, but
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there were many contrary objections for this report
because this analysis was conducted using compari-
son with placebo of other clinical trials. However, oc-
currence of thrombosis after treatment with cele-
coxib has been reported32 in 4 patients with connec-
tive tissue diseases including anti-phospholipid anti-
body syndrome．
PGI2 production in patients with atherosclerosis is
not only via COX-1, but also via COX-2. 33 In other
words, because COX-2 inhibitors reduce PGI2 pro-
duction by inhibition of COX-2 in the vascular epithe-
lium without inhibiting COX-1 in platelets , there is
the possibility that thrombosis may be augmented by
use of any kinds of selective COX-2 inhibitors com-
pared with conventional NSAIDs. Whelton et al.34 re-
ported that rofecoxib increased systolic blood pres-
sure in aged patients with osteoarthritis more than
that of users of celecoxib.
In the end of September 2004, Merck announced
withdrawal of rofecoxib from the market throughout
the world. This decision was due to the result of the
increased incidence of myocardial infarction in rofe-
coxib group when compared with placebo group in
the long-term clinical study to see the prevention of
polyps. Safety of celecoxib and other selective COX-2
inhibitors, or even conventional NSAIDs are just un-
der discussion. Although further detailed studies are
needed, it seems to be better for patients who are
predisposed to thrombosis to avoid use of selective
COX-2 inhibitors．
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